Literature DB >> 34097990

Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.

Tingting Zheng1, Zhengxiang Zhang2.   

Abstract

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and abnormal aggregates of α-synuclein protein called Lewy bodies. To date, there is no drug that can definitely slow down or stop the progression of this disease. The discovery of the cell-to-cell transmission of pathologic α-synuclein seeds offers the possibility to explore novel treatment strategies to prevent the spread of α-synuclein, with the purpose of slowing down the progression of PD in its tracks. Although recent studies have made tremendous progress in understanding how α-synuclein spreads throughout the brain, neuroinflammation seems to play a crucial role in the development of α-synuclein pathology in PD. The activation of microglia, one of the hallmarks of the neuroinflammatory process, is suggested to influence the neuron-to-neuron transmission of α-synuclein. This review summarizes how activated microglia facilitate this process, and focuses on the following mechanisms including the activation of microglia in PD, the reduced ability of activated microglia to clear α-synuclein and increased migratory capacity of microglia in PD, as well as the cooperation between microglia and exosomes in mediating α-synuclein release and propagation. In conclusion, this article help collate information on microglia in-relation to PD.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Microglia; Neuroinflammation; Parkinson's disease (PD); α-synuclein; α-synuclein propagation

Mesh:

Substances:

Year:  2021        PMID: 34097990     DOI: 10.1016/j.neuint.2021.105094

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  6 in total

Review 1.  Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.

Authors:  Erin John Rieger de Almeida; Hélio Jungkenn Ibrahim; Maria Rosa Chitolina Schetinger; Cinthia Melazzo de Andrade; Andréia Machado Cardoso
Journal:  Neurochem Res       Date:  2022-08-13       Impact factor: 4.414

2.  Exosomes in the Field of Neuroscience: A Scientometric Study and Visualization Analysis.

Authors:  Junzi Long; Yasu Zhang; Xiaomin Liu; Mengyang Pan; Qian Gao
Journal:  Front Neurol       Date:  2022-05-17       Impact factor: 4.086

3.  CREB1K292 and HINFPK330 as Putative Common Therapeutic Targets in Alzheimer's and Parkinson's Disease.

Authors:  Rohan Gupta; Pravir Kumar
Journal:  ACS Omega       Date:  2021-12-16

Review 4.  Emerging Potential of Exosomal Non-coding RNA in Parkinson's Disease: A Review.

Authors:  Peng Zhang; Madiha Rasheed; Junhan Liang; Chaolei Wang; Lin Feng; Zixuan Chen
Journal:  Front Aging Neurosci       Date:  2022-03-10       Impact factor: 5.750

5.  SIRT3 expression alleviates microglia activation‑induced dopaminergic neuron injury through the mitochondrial pathway.

Authors:  De-Qi Jiang; Qing-Min Zang; Li-Lin Jiang; Cheng-Shu Lu; Shi-Hua Zhao; Lan-Cheng Xu
Journal:  Exp Ther Med       Date:  2022-09-07       Impact factor: 2.751

Review 6.  Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications.

Authors:  Yassamine Ouerdane; Mohamed Y Hassaballah; Abdalrazeq Nagah; Tarek M Ibrahim; Hosny A H Mohamed; Areej El-Baz; Mohamed S Attia
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.